Navigation Links
SEQUEL Trial Results for Qnexa® Published in AJCN Show 10% Sustained Weight Loss Over 2 Years
Date:12/8/2011

eratogenic risk of topiramate; results of the REMS or cardiovascular outcomes for obesity advisory meetings; the outcome of the second advisory committee meeting for Qnexa; the impact, if any, of the agreement by one of our competitors with an obesity compound to conduct or complete a cardiovascular outcomes study pre-approval; impact on future sales based on specific indication and contraindications contained in the label and extent of the REMS, distribution and patient access program; the FDA's response to the NDA filed for avanafil; our ability to successfully commercialize or establish a marketing partnership for avanafil or our partner's ability to obtain regulatory approval to manufacture and adequately supply avanafil for commercial use; our history of losses and variable quarterly results; substantial competition; risks related to the failure to protect our intellectual property and litigation in which we may become involved; uncertainties of government or third party payer reimbursement; our reliance on sole source suppliers; our limited sales and marketing efforts and our reliance on third parties; failure to continue to develop innovative investigational drug candidates and drugs; risks related to the failure to obtain FDA or foreign authority clearances or approvals and noncompliance with FDA regulations; our ability to demonstrate through clinical testing the safety and effectiveness of our investigational drug candidates; our dependence on the performance of our collaborative partners; the timing of initiation and completion of clinical trials and submissions to the FDA or foreign authorities; the volatility and liquidity of the financial markets; our liquidity and capital resources; and our expected future revenues, operations and expenditures.  As with any pharmaceutical in development, there are significant risks in the development, the regulatory approval, and commercialization of new products. There are no guarantees that our response to the
'/>"/>
SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
2. Data From QNEXA Sequel Study Featured at the 47th EASD Annual Meeting
3. SequelMed EMR Version 8 Certified by Ohio Board of Pharmacy
4. Sequel Systems, Inc. Meaningful Use EHR Receives ONC-ATCB 2011/2012 Certification
5. Sequella and University of Maryland Restate Exclusive License for Jointly Owned Event Marker System Technology
6. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
7. Sequella Lead Drug Compound SQ109 Selected for Phase 1B Clinical Trial Program
8. Sequella Presents Data on Synergy Between Investigational New TB Drugs SQ109 and TMC207
9. TIs new MSP430™ microcontrollers enable more performance and higher precision in home automation, industrial and portable medical applications
10. GiiResearch.com: Computed Tomography (CT) Systems - Technological Advances and Positive Clinical Trial Evidences to Drive the Market
11. GiiResearch.com: Insulin Pumps - Availability of Reimbursement and Favorable Clinical Trial Data to Drive Market Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 24, 2014 /CNW/ -   ... after Health Canada tests confirmed it contains two undeclared ... and phenylpropylmethylamine). The distributor, Empire Health Distribution of ... from retail stores across Canada . ... for weight loss and increased energy. ...
(Date:12/24/2014)...  Novastem, a leader in regenerative medicine, announces ... study for ischemic stroke at Clinica Santa Clarita. ... account for 87 percent of all stroke cases. ... study, entitled "Internal Research Protocol in Combination Therapy ... and Intrathecal Administration of Neural Stem Cells in ...
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc (NYSE: ... Company has received a complete response letter from ... its New Drug Application (NDA) for the fixed-dose ... treatment of hypertension.   Photo - ... disappointed in the receipt of a complete response ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... DUSA Pharmaceuticals, Inc.® (Nasdaq: DUSA ), a ... it has been named to Deloitte,s 2010 Technology Fast ... DUSA as one of the Top 500 fastest growing ... in North America.  Rankings are based on percentage of ...
... Oct. 26 Neurocrine Biosciences, Inc. (Nasdaq: NBIX ... Officer of Neurocrine Biosciences, will be presenting at the Oppenheimer ... The live presentation takes place on Tuesday, November 2, ... Time.  The presentation will be webcast and may be accessed ...
Cached Medicine Technology:DUSA Pharmaceuticals Named to Deloitte's 2010 Technology Fast 500 List of Fastest Growing Companies in North America 2
(Date:12/24/2014)... 25, 2014 Over 700 toys, that’s ... local communities. That is 700 smiling little faces this ... Additionally over $6000 in monetary donations was given to ... of the expenses they incur through the year. Some ... A Child's Haven , Shrine's Children's Hospitals, Toys ...
(Date:12/24/2014)... Connie Casad, MD, a well-known and respected gynecologist, ... years of practice experience in Dallas, Texas, has announced ... dietary detoxification. The second study is scheduled to begin ... test patients who just completed a 21-day detoxification regimen. ... conducting the study, Dr. Casad said, "About 10 years ...
(Date:12/24/2014)... 24, 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ... tort litigation currently underway in Pennsylvania’s Philadelphia Court of ... December 24, 2014, court documents indicate that 1,183 claims ... individuals who developed gynecomastia (male breast growth) and other ... Court indicates that this represents an increase of more ...
(Date:12/24/2014)... (PRWEB) December 24, 2014 Dr. Vu ... the expansion of his practice and med-spa with the ... practice’s growing list of cosmetic treatments and services. , ... into the skin,” says Dr. Ho. “As a result ... such as wrinkles, sun spots, discolorations or blemishes.” , ...
(Date:12/24/2014)... Today, UWDress.com, the famous women’s dress supplier, has presented ... a site-wide wedding gown promotion. , For those ... more unexpected way, the collection should be a great choice. ... market, and they are available with custom service. , Now, ... prices, up to 75% off; most of them come in ...
Breaking Medicine News(10 mins):Health News:AlignLife Donates Over 700 Toys This Year 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 2Health News:Connie Casad, MD, Now Accepting Test Participants for January Dietary Detoxification Study 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Dr. Vu Ho Expands Facial Plastic Surgery Practice to Include New Skin Care Treatment 2Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2
... Misonix, Inc. (Nasdaq: MSON ), a developer ... Europe is used for the ablation of tumors and ... attendance and participation in the annual Diabetic Foot Global ... March 19-21, 2009. In addition to exhibiting its ...
... to Require Coverage of CT ColonographyRESTON, Va., May ... Medicare and Medicaid Services (CMS) to not cover ... virtual colonoscopy, exams is not supported by the ... of thousands of unnecessary deaths each year from ...
... ISELIN, N.J., May 12 Pharmos Corporation (Pink Sheets: PARS) ... 2009. The Company recorded a net loss of $3.7 million, ... to a net loss of $3.6 million, or $0.14 per ... totaled $2.9 million at March 31, 2009.The slight increase in ...
... BioMed Realty Trust, Inc. (NYSE: BMR ) today ... of its common stock pursuant to an effective shelf registration ... expects to use the net proceeds of the offering to ... million unsecured line of credit and for other general corporate ...
... for activity area at May 9 eventATLANTA, May 12 ... the first Bright Starts Kids for the Cure Korral at ... past Saturday, May 9 at Atlantic Station in Midtown Atlanta, ... a refreshing drink as they enjoyed fun activities like carnival ...
... Particularly Concerning in Older AmericansWASHINGTON, May 12 ... its third annual report on top longevity research ... the report here: , ... was joined by Carey Gleason, Ph.D., Associate Scientist/Geriatric ...
Cached Medicine News:Health News:Misonix Announces Participation in Annual Diabetic Foot Global Conference 2Health News:Misonix Announces Participation in Annual Diabetic Foot Global Conference 3Health News:CMS Denial of Coverage for Virtual Colonoscopy May Cost Lives 2Health News:CMS Denial of Coverage for Virtual Colonoscopy May Cost Lives 3Health News:Pharmos Corporation Reports 2009 First Quarter Results 2Health News:Pharmos Corporation Reports 2009 First Quarter Results 3Health News:Pharmos Corporation Reports 2009 First Quarter Results 4Health News:Pharmos Corporation Reports 2009 First Quarter Results 5Health News:BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock 2Health News:BioMed Realty Trust Announces Public Offering of 14,000,000 Shares of Common Stock 3Health News:Parents, Kids Enjoyed Kids Korral at Annual Komen Atlanta Race for the Cure 2Health News:KLRI Releases 3rd Annual Report On Year's Top Longevity Research Findings 2Health News:KLRI Releases 3rd Annual Report On Year's Top Longevity Research Findings 3Health News:KLRI Releases 3rd Annual Report On Year's Top Longevity Research Findings 4
Facial Wrap...
Four way compression with five contact closures...
Chin Support...
CDIs Abdominal Binders are designed with a non-pitching, body contouring, non-rolling elastic band that provides both support and compression. Available in 9, 12 and 15 widths with waist ranges from ...
Medicine Products: